Evidence map›Paper›PMID 34104813›Full record

ArticleJournal of clinical and translational research2021

Reliability and concurrent validity of TRAZER compared to three-dimensional motion capture.

Jennifer A Hogg, Lynette M Carlson, Abigail Rogers, Mason W Briles, Shellie N Acocello, Gary B Wilkerson

Open access · greenAbstract read
In one paragraph

Article in Journal of clinical and translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jennifer A HoggDepartment of Health and Human Performance, The University of Tennessee Chattanooga, Chattanooga, TN, USA.
Lynette M CarlsonDepartment of Health and Human Performance, The University of Tennessee Chattanooga, Chattanooga, TN, USA.
Abigail RogersIntercollegiate Athletics, University of Missouri, Columbia, MO, USA.
Mason W BrilesEmory Sports Medicine Center, Emory Healthcare, Atlanta, GA, USA.
Shellie N AcocelloDepartment of Health and Human Performance, The University of Tennessee Chattanooga, Chattanooga, TN, USA.
Gary B WilkersonDepartment of Health and Human Performance, The University of Tennessee Chattanooga, Chattanooga, TN, USA.
University of Tennessee at Chattanooga · USEmory Healthcare · USUniversity of Missouri · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEfficient neural processing of visuospatial and proprioceptive input appears to be crucial for avoidance of sport injury. As such, clinically-feasible tests are needed to identify deficiencies found by advanced neuroimaging and electrophysiological tests. Three-dimensional motion capture in a laboratory setting is currently the gold standard for measurement of human movement parameters but is costly and requires extensive training. Non-immersive virtual reality systems with body motion tracking, such as TRAZER, may provide a clinically-feasible and portable means of acquiring similar variables. Test-retest reliability and concurrent validity of these systems are currently lacking.

aimThe aim of the study was to assess the concurrent validity of the TRAZER single-camera system with 3D motion capture system and to assess the test-retest reliability of TRAZER's whole-body reactive agility metrics.

methodsParticipants - For validity, 13 healthy individuals (24.8±3.1 years, 170.0±7.7 cm, 70.0±14.2 kg); for reliability, 18 healthy individuals (23.3±2.5 years, 168.2±11.2 cm, 78.2±17.8 kg). Design - Validity was a single-session cross-sectional study. Reliability was a 3 consecutive day test-retest study. Setting-Controlled laboratory study. Intervention - Assessments utilized randomized movements in eight directions for forty total repetitions as designated by the TRAZER system. TRAZER protocol was simultaneously tracked by Vicon Motion Capture and the TRAZER system. Reliability data were captured on three consecutive days by the TRAZER system. Main Outcome Measures - Maximum acceleration, maximum velocity, and total distance were recorded for validation. In addition to these measures, maximum deceleration, average velocity, average acceleration, average deceleration, and average reaction time were collected for reliability.

resultsOverall, a lack of agreement exists between maximum outputs for TRAZER and 3D motion capture (velocity r=0.808, acceleration r=-0.090), but total distance correlation was high (r =.961). ICC values between days 1-2-3 for average measures were high (average velocity=0.847, average acceleration=0.919, and average deceleration=0.948) with the exception of average reaction time being fair (ICC=0.536). ICCs for maximum measures showed a much smaller correlation between days (velocity=0.654, acceleration=0.171, and deceleration=0.416).

conclusionsEven though there is a lack of strong concurrent validity between measures obtained from TRAZER and 3D motion capture systems, there is strong test-retest reliability of the TRAZER system. The applicability of these findings makes TRAZER clinically relevant in scenarios requiring pre- and post-testing for return to play decisions, or monitoring of a training regimen where demonstration of validation to a gold standard measurement is not relevant. RELEVANCE FOR PATIENTS: When test-retest capability is desired, such as in return-to-play protocols following an injury, Trazer is a reliable option.

Indexed as

functional performancekinectreactive agilityvirtual reality

Identifiers

PMID34104813
PMCPMC8177031
OpenAlexW3167389781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.